Dr. Berenson is the founder and principal of ONCOtherapeutics, a prolific specialty practice in West Hollywood, CA focused on the treatment of patients with multiple myeloma and related malignancies and conditions. More than 600 patients under his care. Dr Berenson is also the CEO of ONCOtherapeutics, a specialized CRO leading preclinical research and clinical trials from phase I to IV in community oncology sites throughout the US.
Dr. Berenson founded the Institute for Myeloma & Bone Cancer Research (IMBCR), a mission-driven 501(C)3 non-profit institute dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Dr. Berenson has authored more than 300 peer-reviewed publications and contributed to multiple book chapters. He serves as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section, and is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr. Berenson serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society.